Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for
belinostat when combined with CHOP regimen and establish the recommended belinostat dose for
the Phase 3 study.